Mr. Reginald (Reg) Dupre has led EPIEN Medical since 1999 and steered it through its start-up and its technology development stages with strong leadership as CEO. During the past five years, Reg has led the company through its commercialization stage and today the company’s products are sold in more than 40 countries. Under Reg’s insightful leadership, the company’s vision to develop and implement a state-of-the-art nonbiologic technology platform has come to fruition. This novel platform technology transcends dental, acute and chronic wound, surgical, dermatological, veterinary, and other medical specialties applications worldwide. He has also guided EPIEN’s marketing efforts to expand brand recognition of its oral healthcare products ORALMEDIC®, HYBENX®, and soon REVITY™ at a global level.
As chairman and CEO of EPIEN Medical, Reg has arranged capital from angel investors to large institutional investments to pave the company’s path to becoming a global leader in advanced non-antibiotic therapies.
Current role